| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
|
Medicine details |
|
| Medicine name | rivaroxaban (Xarelto®) |
| Formulation | 2.5 mg tablet |
| Reference number | 2082 |
| Indication | Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with coronary artery disease or symptomatic peripheral artery disease at high risk of ischaemic events |
| Company | Bayer Healthcare Pharmaceuticals |
| BNF chapter | Cardiovascular system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 07/11/2018 |
| NICE guidance | |